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Primary cutaneous CD30-positive T-cell lymphoproliferative disor-ders are the second most common subgroup of cutaneous T-celllymphomas. They include two clinically different entities with
some overlapping features and borderline cases: lymphomatoid papulosis
and primary cutaneous anaplastic large cell lymphoma. Molecular studies
of primary cutaneous anaplastic large cell lymphoma reveal an increasing
level of heterogeneity that is associated with histological and
immunophenotypic features of the cases and their response to specific
therapies. Here, we review the most significant genetic, epigenetic and
molecular alterations described to date in primary cutaneous CD30-pos-
itive T-cell lymphoproliferative disorders, and their potential as therapeu-
tic targets.
Introduction
CD30+ primary cutaneous T-cell lymphoproliferative disorders are the second
most common subgroup of cutaneous T-cell lymphomas after mycosis fungoides
(MF), accounting for approximately 30% of cases.1 These cutaneous lymphomas
have customarily been classified on the basis of their clinical presentation into lym-
phomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma
(pcALCL) and borderline cases. In recent years, genomic analysis has become
important for the diagnosis and clinical management of patients affected by sys-
temic and cutaneous hematologic malignancies.2 Systemic anaplastic large cell lym-
phoma (ALCL) is defined by mutually exclusive rearrangements of ALK,
DUSP22/IRF4 and TP63, which have prognostic and survival implications and
must be taken into account in the management of patients.2 pcALCL have
histopathological and immunophenotypic similarities with systemic ALCL, but
have a more indolent behavior. Chromosomal translocations described in systemic
ALCL can also be seen in pcALCL, although they have different clinical implica-
tions. Thus, there are some ALK+ pcALCL, and some cases of LyP and pcALCL
share a DUSP22-IRF4 locus translocation. Bearing all this in mind, we have
reviewed the molecular alterations in CD30+ primary cutaneous T-cell lymphopro-
liferative disorders, describing the various molecular alterations and considering
their clinical and therapeutic implications. 
Lymphomatoid papulosis
LyP is an enigmatic disease that follows the course of a chronic skin condition
and has the histology of a lymphoma. It typically has a recurrent, self-healing
course, with an excellent prognosis.3 Clinical features of all types of LyP are similar
and consist of papular, papulonecrotic and/or nodular skin lesions at different
stages of evolution. The number of lesions is, however, highly variable, ranging
from only a few lesions to hundreds. Likewise, there is great variability in the dura-
tion of lesions, which may be present for a few weeks or persist for decades. Lyp
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is seen more frequently in adult patients, but children can
also be affected.4
Customarily, on the basis of its extremely variable
histopathology, LyP has been divided into five types with
similar prognosis, although distinguishing them is impor-
tant for the differential diagnosis from more aggressive
types of lymphoma.5 Although more descriptive terms
have been proposed, in 2017 the World Health
Organization (WHO) categorized LyP using consecutive
alphabetical letters.6 Type A is the most frequent form of
LyP, accounting for 80% of cases. Tumor cells are typically
CD4+ and CD30+ and appear scattered or in small clusters,
accompanied by numerous inflammatory cells, including
neutrophils, eosinophils and small lymphocytes. The
main differential diagnoses include reactive lesions, such
as insect bites, and pityriasis lichenoides et varioliformis
acuta (PLEVA).7 Type B is uncommon, accounting for 5%
of cases, and has the same CD4+, CD8– immunopheno-
type.7 It has a histology similar to that of plaque-stage MF
with an epidermotropic infiltrate of small, atypical CD30+
cells, which is its main differential diagnosis; less frequent-
ly it must be distinguished from cutaneous epidermotrop-
ic gamma/delta lymphoma.5 Type C makes up around
10% of LyP cases and has a histology very similar to that
of pcALCL, with a nodular cohesive infiltrate of large
CD30+, CD4+, CD8– pleomorphic and anaplastic tumor
cells featuring mitotic figures and abundant cytoplasm.7
Apart from pcALCL, other entities, such as transformed
MF, peripheral T-cell lymphoma not otherwise specified,
and adult T-cell lymphoma/leukemia, may have a similar
histology.5 Types D and E have only been described rela-
tively recently, and are usually characterized by a cytotox-
ic phenotype, with CD8+ and CD30+ lymphocytes.
Biopsies from patients with type D LyP show prominent
epidermotropism of atypical small-to-medium-sized pleo-
morphic cells. There may be deep dermal and perivascular
infiltrates. This variant accounts for about 5% of cases and
needs to be differentiated from pagetoid reticulosis, a
peculiar CD8+ form of MF, from more aggressive lym-
phomas such as primary cutaneous aggressive epider-
motropic CD8+ cytotoxic T-cell lymphoma, and from
cutaneous gamma/delta lymphoma.8 Accounting for
fewer than 5% of cases, type E LyP shows more extensive
necrosis and ulceration due to angiocentric and angiode-
structive infiltrates of mostly medium-sized, pleomorphic
CD8+ and CD30+ lymphocytes with hemorrhage, vascular
occlusion and thrombi, admixed with some eosinophils.9
Although clinically indolent, the histology can be con-
fused with that of extranodal NK/T-cell lymphoma, nasal
type, cutaneous gamma/delta lymphoma or ALCL (prima-
ry cutaneous or systemic form) with angiocentric and
angiodestructive growth. It is important to highlight that
histological differential diagnoses of LyP (such as aggres-
sive epidermotropic CD8+ cytotoxic T-cell lymphoma or
MF) must be excluded by clinicopathological correlation
based on characteristic clinical grounds with the typical
"waxing and waning" presentation of LyP.
Recently, the detection of rearrangements of the
DUSP22-IRF4 locus on chromosome 6p25.3 has enabled
the identification of a new molecular-based type of LyP
with a characteristic histological pattern.10
Lymphomatoid papulosis with 6p25.3 rearrangements 
This molecular alteration at the DUSP22-IRF4 locus is
less frequent in LyP than in pcALCL and accounts for
fewer than 5% of cases of LyP. Typically, patients are older
than those with other forms of LyP, and their lesions are
characterized by a biphasic histological pattern showing,
on the one hand, extensive epidermotropism with CD30+
small-to-medium-sized T-lymphocytes that simulate
pagetoid reticulosis lesions and, on the other, a dermal
neoplastic infiltrate composed of large T cells with strong
CD30 positivity.11
T-cell receptor clonality
Detection of T-cell receptor clonality differs significantly
between LyP types.12 This difference might be related to
the number of tumor cells present in the infiltrate, which
is lower in type A than in type C, hindering the detection
technique in paraffin-embedded tissues. LyP presents
atypical evolution for a peripheral T-cell lymphoma,
exhibiting self-healing lesions and multiple outbreaks. T-
cell receptor clonality studies have been performed in var-
ious LyP lesions to investigate the potential role of foreign
antigens and the relationship between LyP and other cuta-
neous T-cell lymphomas in cases with overlapping histo-
logical findings. Chott et al. showed that multiple skin
lesions and associated T-cell lymphomas (MF and ALCL)
were clonally related in most LyP patients, which suggests
that a non-random genetic event initiates the disease.13
Shared clonality has been confirmed for LyP and MF
lesions occurring in the same patients by de la Garza
Bravos et al.14
T-cell receptor-γ expression is considered a feature of
primary cutaneous gamma-delta T-cell lymphoma, and is
rare in other types of primary cutaneous lymphoma.
However, there are cases of type D LyP with a cytotoxic
phenotype and T-cell receptor-γ expression that, unlike in
primary cutaneous gamma-delta T-cell lymphoma, is not
associated with worse prognosis.15
Other findings in lymphomatoid papulosis
SATB1 (special AT-rich sequence-binding protein 1) is an
important thymocyte nuclear protein, a chromatin organ-
izer that is crucial to the development of T-lympho-
cytes.16,17 SATB1 plays a role in inducing resistance to the
death of Sézary cells and has been implicated in the patho-
genesis of the leukemic form of cutaneous T-cell lym-
phoma-Sézary syndrome.18 Sun et al. investigated its
expression in a large cohort of patients with CD30+ lym-
phoproliferative disorders, and studied the potential for its
use in classifying CD30+ lymphoproliferative disorders
with differential clinicopathological behaviors and prog-
noses.19 They identified SATB1 expression in anaplastic T
cells in 91.7% of LyP cases and in 38.1% of pcALCL cases.
SATB1 cases showed T-helper 17 polarization with
expression of T-helper 17 cytokines and repressed T-
helper 1-related genes.19 They also described a better
response to methotrexate and interferon treatment in
cases with high levels of SATB1 expression.  Furthermore,
these cases showed more prominent epidermal hyperpla-
sia and granulocytic infiltration.19 Sun et al. postulated that
the variability of SATB1 expression in CD30+ lymphopro-
liferative disorders could be related to the extent of DNA
methylation.19
Tumor necrosis factor receptor (TNFR)-associated factor
1 (TRAF1) is involved in intracellular signal transduction of
a range of TNFR, including CD30 and those associated
with nuclear factor-kB activation.20 Assaf et al. studied the
expression of TRAF1 using one antibody that recognized
CD30+ primary cutaneous LPD
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a formalin-resistant epitope (Ber-TRAF1A). They found
strong TRAF1 expression in the tumor cells in most LyP
cases, in contrast to tumor cells of primary and secondary
pcALCL, in which TRAF1 expression was much more
restricted.21 Benner et al. also studied this marker in con-
junction with MUM1, Bcl2 and CD15, but found it to be
of no prognostic or diagnostic utility.22 We review the role
of apoptosis in LyP pathogenesis in greater depth in the
section on pcALCL, below. 
Mahtas et al. studied gene deregulation and spatial
genome reorganization near the ALCL translocation
breakpoint in ALCL. They described the aberrant expres-
sion of Fra2 and of Id2 in LyP, the latter being consistent
with the findings of Cotta et al.23,24 They found a lower
level of expression in LyP compared with systemic ALCL
and argued that gene dosage could be involved in the inva-
siveness and progression of LyP.23
P53 mutations have rarely been found in LyP. Kapur et
al. reported two cases of LyP with P53 mutations from an
analysis of 11 exons of the P53 gene. They found P53
mutations to be infrequent in cutaneous CD30+ lympho-
proliferative disorders, and the two patients with LyP who
harbored the mutation did not show any changes in the
clinical behavior of the disease.25
Notch1 expression has been identified in LyP tumor
cells, in which it is associated with the expression of the
Notch1 ligand Jagged1, but not of the Delta1 ligand,
which was expressed at low or negligible levels.26 The lev-
els of expression of Notch1 and Jagged1 were higher in
pcALCL samples, a finding that is discussed in greater
detail in the section on pcALCL, below.
To date, no ALK fusions have been reported in LyP, in
contrast to pcALCL, and no TP63 rearrangements have
been found in these patients.25,27,28
Primary cutaneous anaplastic large cell 
lymphoma
pcALCL is, by definition, a CD30+ large T-cell neoplasm
composed of large cells with an anaplastic, pleomorphic or
immunoblastic morphology. The CD30 antigen is
expressed in more than 75% of tumor cells. pcALCL
resembles other forms of ALCL but arises primarily in the
skin.1 The clinical course of pcALCL differs from that of
systemic forms of ALCL, both ALK+ and ALK-, which
explains why it has been classified as a distinct category.29
However, there is some overlap between systemic and
primary cutaneous forms of ALCL, whereby they share
some molecular alterations, suggesting that other genetic
and biological differences are likely to exist and therefore
need to be identified.30
Primary cutaneous large T-cell lymphoma may also be
the result of MF tumor progression. Thus, in patients with
pcALCL, a current or previous diagnosis of MF must be
excluded. The differential diagnosis between pcALCL and
transformed CD30+ MF may be challenging, except when
there is a clinical presentation with a previous or simulta-
neous patch-plaque stage MF lesion. Genetic differences
between pcALCL and transformed MF have been found
using array-based comparative genomic hybridization.31
From a clinical point of view, patients with pcALCL typi-
cally present with solitary or localized nodules or tumors
or, more unusually, papules, with frequent ulceration and
rapid evolution in some cases that may simulate aggres-
sive lymphomas. The presence of multiple lesions in 20%
of cases can hinder the differential diagnosis with type C
LyP, which features borderline lesions.7 This cutaneous
lymphoma occurs predominantly in males (male:female
ratio 3-2:1). It is more frequent in people in their sixth
decade, but may also appear in childhood.32 It has been
reported that pcALCL is a common form of cutaneous
lymphoma in immunosuppressed patients, such as indi-
viduals infected with human immunodeficiency virus and
organ transplant recipients.33,34 However, in contrast to
what usually happens in patients with B-cell lymphomas
with CD30+ large cells, especially in immunosuppressed
patients, expression of Epstein-Barr virus by the tumor
cells is extremely rare or absent in pcALCL with the T/null
cell phenotype.32 When it does appear, it is essential to rule
out a diagnosis of a B-cell lymphoma with T-cell markers
and CD30 expression, such as plasmablastic lymphoma or
primary effusion lymphoma. 
There is extracutaneous involvement in about 10% of
cases, usually with infiltration of locoregional lymph
nodes. In these cases it is important to establish the
sequence of presentation in order to rule out cutaneous
involvement by systemic ALCL, which has an entirely dif-
ferent prognosis. Characteristically, locoregional lymph
node involvement is not related to bad prognosis in
pcALCL. Clinical presentation with extensive skin lesions
on legs or arms is the only risk factor associated with a sta-
tistically significantly worse prognosis.7,35,36
The classic histological pattern described in pcALCL
consists of a circumscribed nodular infiltrate that is mostly
dermal, composed of arranged large lymphoid cells and
usually with absent or subtle epidermotropism5 (Figure 1).
However, several variants of this histological pattern have
been described, some of which are related to molecular
findings described later in this review.5 Neutrophils and
eosinophils are usually scattered in classic forms, although
rich variants, which are usually more common in
immunosuppressed patients, have been reported. The
presence of this rich granulocytic infiltrate may be
explained by the release of interleukin-8, whose levels are
elevated in cultured tumor cells and in the serum of these
patients.37 Other unusual histological presentations of
pcALCL have been reported, including angiocentric or
angiodestructive forms,38,39 subcutaneous and keratoacan-
thoma-like forms,40 sarcomatoid variants with prominent
spindle-cell morphology,41 small cell variants that are rarer
than in systemic forms of ALK+ ALCL,42 and an intravascu-
lar ALCL that may involve the skin and must be distin-
guished from the more common intralymphatic spread of
tumor cells in pcALCL, which seems to have no prognos-
tic implications.43,44
pcALCL cells usually carry an activated T-cell pheno-
type in which CD30 is expressed in more than 75% of
tumor cells (the hallmark of the disease) (Figure 1), fre-
quently accompanied by CD3, CD4 and CD45RO
expression and varying degrees of loss of CD5 and CD2.
The expression of other activation markers, such as
CD71, HLA-DR and CD25 (IL-2R), has been noted in
approximately half of the cases. Cytotoxic markers
(TIA1, perforin and granzyme B) and cutaneous lympho-
cyte antigen (CLA, HECA-452) may also be found in
around half of the patients.45 In contrast to systemic ALK–
ALCL, in which approximately 43% of cases are EMA+,46
EMA is often negative or only focally positive in
pcALCL. Interestingly, pcALCL shares with transformed
MF and Sézary syndrome the expression of KIR3DL2
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(CD158k) by neoplastic cells, a potential target reviewed
in the next section.47
Altered expression of the T-cell receptor/CD3 complex,
T-cell receptor-associated transcription factors and signal
transduction molecules is a common feature of systemic
and cutaneous CD30+ lymphoproliferations, a finding that
may be of potential diagnostic utility.48
Monoclonal rearrangement of the TCR gene occurs in
65% to 90% of cases of pcALCL in contrast with a much
lower frequency in LyP types A and B.12,49
Genetic variants of primary cutaneous anaplastic large
cell lymphoma
pcALCL seems to carry the same molecular alterations as
systemic ALCL, but with dramatic differences in frequen-
cies. From the molecular point of view, most pcALCL cases
would currently be classified as triple-negative (ALK-,
DUSP22-, TP63-negative), since they do not carry any of
these precise underlying molecular alterations. However,
these lymphomas have an entirely different prognosis
from their systemic counterparts, with some of them
showing spontaneous regression and an absence of pro-
gression, with long-term survival in the vast majority of
the cases (Figure 1). The molecular alterations present in
pcALCL are, in descending order of frequency: (i) DUSP22
rearrangements (Figure 2);11,50-61 (ii) ALK translocations
(Figure 3);62-65 (iii) TP63 rearrangements;27,66 and (iv) NPM1-
TYK2 gene fusion.67-69 ALK translocations are much less
frequent than in systemic lymphomas, having been
described in isolated cases or very small series.63-65 TP63
rearrangements and NPM1-TYK2 gene fusion are excep-
tional and only isolated cases have been reported.27,67-69
ALK-negative primary cutaneous anaplastic large cell lymphoma
with DUSP22 rearrangements 
DUSP22 rearrangements in systemic ALK– ALCL have
been associated with a better prognosis, similar to that of
ALK+ systemic ALCL, compared with TP63-translocated
or triple-negative cases.50,51 About 20% of pcALCL cases
harbor the DUSP22-IRF4 translocation, with no correla-
tion with MUM1/IRF4 protein expression.11,52,53 First
reported in LyP, a particular biphasic histological pattern
has been linked to the presence of DUSP22 rearrange-
ments in pcALCL (Figure 2). This pattern is characterized
CD30+ primary cutaneous LPD
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Figure 1. “Classic”, ALK-, DUSP22-, TP63- (triple negative) primary cutaneous
anaplastic large cell lymphoma. (A) Clinical picture showing two adjacent
tumoral erythematous nodules located in the scapular region simulating der-
matofibrosarcoma protuberans. (B,C) (x40), Hematoxylin & eosin stain showing
the dermal infiltration consisting of a circumscribed infiltrate, composed of
arranged large lymphoid cells with absent or subtle epidermotropism. (D,E)
(x40), CD30 stain showing positivity in the membrane and Golgi of the tumoral
large cells.
Figure 2. ALK-negative primary cutaneous anaplastic large cell lymphoma
with DUSP22 rearrangements. (A) Clinical picture of a large ulcerated tumor in
the left malar region of an elderly woman  showing (B) the typical CD30 staining
of a case of pcALCL with DUSP22 rearrangement (Ref. 58, courtesy of Onaindia
et al.), evidencing extensive epidermotropism with CD30+ small-to-medium-
sized T-lymphocytes that simulate pagetoid reticulosis lesions. (C) Hematoxylin
& eosin-stained panoramic view of the case in (E) and (F) showing the tumor
nodule with profuse dermal involvement. (D) Detail, stained with hematoxylin &
eosin, of another case exemplifying the biphasic epidermal and dermal lympho-
cytic infiltrate. (E,F) (x40), CD3 stain highlights the intraepidermic neoplastic T
cells in another case with DUSP22 rearrangement. 
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by the simultaneous presence of dermic CD30+ large cells
and intraepidermal infiltrate by CD30+ small cells with a
pagetoid reticulosis pattern.10,54 The clinical behavior and
prognosis of cases with DUSP22 rearrangements is simi-
lar to that of cases without such rearrangements.55
Currently, clinical presentation and staging remain essen-
tial to differentiate cases of pcALCL with DUSP22
rearrangement from LyP with this molecular alteration,
because the two entities have similar histological fea-
tures.54 DUSP22 rearrangements have also been described
in rare cases of CD30-rich tumoral MF.56
Expression of the chemokine receptor gene CCR8 is asso-
ciated with DUSP22 rearrangements in ALCL.57 It has been
proposed that the higher level of expression of this skin-
homing chemokine receptor may explain the lower tenden-
cy of pcALCL to disseminate to extracutaneous sites.58
The pathways activated after DUSP22-IRF4 rearrange-
ments in peripheral T-cell lymphomas have recently been
investigated by Mélard et al.59 They found a tumor suppres-
sor function for DUSP22, with the restored expression of
DUSP22 promoting apoptosis and impairing soft agar
clonogenicity.59 Negative regulation of the interleukin-
6/leukemia inhibitory factor/signal transduction and activa-
tor of transcription (STAT)-3 pathway has been found in
experimental studies.60 Consistent with these findings,
DUSP22 (also known as JKAP) knockout mice develop
inflammation and autoimmunity.61
ALK-positive primary cutaneous anaplastic large cell lymphoma 
Cutaneous involvement in cases of systemic ALK+ ALCL
is generally indicative of a bad prognosis (relative risk: 2)
and occurs in 26% of pediatric ALK+ ALCL cases.62 In con-
trast, ALK+ pcALCL cases seem to have a more favorable
outcome. Only a few cases of ALK+ pcALCL have been
reported, the largest series being that described by Oschlies
et al.,63 in which six pediatric patients with ALK+ pcALCL
had a favorable clinical course, comparable to that of
patients with ALK– pcALCL. Other ALK+ primary cuta-
neous cases occurred in adults and had peculiar features,
such as cytoplasmic ALK expression and a lack of ALK
translocation.64 To date, no ALK fusion partners exclusive to
the primary cutaneous cases have been reported. It is
important to stage patients with ALK+ pcALCL carefully
because cutaneous lesions triggered by insect bites can be
the first manifestation of systemic ALK+ ALCL.65 The
authors postulated that insect bite-associated antigens may
attract T lymphocytes to the skin, some of which bear the
ALK translocation t(2;5). The subsequent release of differ-
ent cytokines at the site of the bite could act as a “second
hit” and activate T cells, which may express the oncogenic
NPM-ALK protein and initiate deregulated growth.65
Primary cutaneous anaplastic large cell lymphoma with TP63
rearrangements  
In 2012, Vasmatzis et al. described two of 19 pcALCL that
carried TP63 rearrangements,27 both of which had an
unusual, aggressive clinical behavior, analogous to that of
systemic ALCL with TP63 rearrangements.51 Subsequent
work by the same group also identified a case of aggressive
MF with a TP63 translocation.66 In both series, TP63 translo-
cations were associated with strong TP63 protein expres-
sion detectable by immunohistochemistry, but this was not
a specific finding since the protein was also expressed in
cases without a TP63 translocation. Schrader et al. reviewed
a series of 17 cases of aggressive LyP and pcALCL. They
found no cases with a TP63 translocation, and confirmed
the lack of specificity of the TP63 immunohistochemistry.28
NPM1-TYK2 gene fusion and oncogenic STAT3 activation
Mutations on the JAK1/STAT3 pathway are common in
systemic ALK– ALCL.67,68 However, these mutations have
been found in only 5% of pcALCL, which is further evi-
dence of the distinct molecular pathogenesis of the two
entities. Whole-transcriptome sequencing done in
pcALCL revealed the NPM1-TYK2 gene fusion, which
encodes a protein containing an intact catalytic domain in
TYK2 and an oligomerization domain of NPM. It was
present in two (1 LyP, 1 pcALCL) of the cases of primary
cutaneous CD30+ lymphoproliferative disorders studied
(n=47) and was not found in other mature T-cell neo-
plasms (n=151). Both cases showed nuclear STAT5 expres-
sion. This defective kinase activates the STAT signaling
pathway (STAT1/3/5), implying that TYK2 could be a
therapeutic target in this subset of patients.69
Epigenetic abnormalities in primary cutaneous
anaplastic large cell lymphoma
Epigenetic abnormalities, including histone tail post-
translational modifications and DNA methylation, are a
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Figure 3. ALK-positive primary cutaneous anaplastic large cell lymphoma. (A)
Clinical picture of a large ulcerated tumor located on the back. (B) Fluorescence
in situ hybridization image showing an ALK reciprocal translocation with gain of
one or two copies of the ALK gene. (C,D) Hematoxylin & eosin stain showing the
morphology of large T cells (E,F) (x40), with CD30 positivity and (G,H) (x40),
nuclear and cytoplasmic ALK positivity in tumor T cells.
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hallmark of cancer and a potential target for therapy.70
DNA methylation profiling studies have not been done
specifically in cutaneous ALCL; data derived from the
analysis of systemic ALCL show an ALK-independent
methylation signature, characteristic of and different from
that of other peripheral T-cell lymphomas, establishing a
relation with the promoter DNA methylation of early T-
cell stages.71
The enhancer of the zeste homolog 2 (EZH2) consti-
tutes the core catalytic subunit of polycomb repressive
complex2 (PRC2) and has a “canonical” function as a
PRC2-dependent lysine 27 of the histone H3 (H3K27)
methylator, which can also methylate a number of non-
histone proteins, thereby promoting transcriptional acti-
vation, and making it a potential therapeutic target.72 Yi et
al. found EZH2 overexpression in pcALCL and large cell
transformed cutaneous T-cell lymphomas, in which it reg-
ulates apoptosis, cell-cycling in the neoplastic cells, and
the interaction between the tumor and its microenviron-
ment.73
Non-coding RNA play an important epigenetic regulato-
ry role that has implications for cell development and can-
cer, above all in the pathogenesis of T-cell lymphomas.74
MicroRNA (miRNA, miR) are small, non-coding RNA
molecules that regulate gene expression at the post-tran-
scriptional level by targeting the 3’-untranslated regions of
messenger RNA to promote their degradation or decrease
their translation.75 Several studies have identified different
miRNA signatures for CD30+ pcALCL.62,76-78 Benner et al.
showed upregulation of an oncogenic miRNA signature in
pcALCL comprising miR-155, miR-27b, miR-30c and miR-
29.77 Sandoval’s study confirmed the upregulation of
miR155 and identified upregulation of miR-21, miR-142-
3p/5p, let-7i, miR-424, miR-431, miR-542-5p, miR-29b-1,
miR-342-p, and miR-484, with downregulation of some
interesting tumor-suppressor miRNA such as miR-
23b/miR-27b, miR-203, miR-205 and miR-125b.78 This
miRNA profile reported for pcALCL differs considerably
from those reported in systemic ALCL, which suggests a
different underlying pathogenic mechanism or reflects dif-
ferences in the microenvironment.79,80
In this setting, epigenetic therapy (histone deacetylase
inhibitors, such as romidepsin or belinostat, and methyla-
tion inhibitors) has shown some benefit in the treatment
of ALCL and cutaneous T-cell lymphomas.81,82 In the
future, more precise identification of miRNA profiling in
pcALCL could allow us to develop specific diagnostic and
progression markers and may lead to the use of more spe-
cific targeted therapies.
NOTCH signaling in primary cutaneous anaplastic large
cell lymphoma
The deregulation of Notch signaling in hematopoietic
cells has been linked to the development of several hema-
tologic malignancies, including acute lymphoblastic T-cell
leukemia, B-cell chronic lymphocytic leukemia, multiple
myeloma, acute myeloid leukemia, Hodgkin lymphoma
and systemic ALCL.83-88 Increased expression of Notch sig-
naling molecules has been described in primary cutaneous
CD30+ lymphoproliferative disorders, as previously men-
tioned.26 The same group found that pcALCL cells
increased their expression of the intracellular domains of
Notch receptors Notch1, Notch2, Notch3 and Notch4, as
well as of the Notch ligand Delta and the product HES1.89
In addition, it was demonstrated that the inhibition of the
Notch pathway through inhibition of gamma-secretase
with gamma-secretase inhibitors induces apoptosis and
decreases cell viability in pcALCL cell lines, findings that
identify the Notch pathway as a potential therapeutic tar-
get in pcALCL.89
CDKN2A-CDKN2B losses in primary cutaneous
anaplastic large cell lymphoma
The CDKN2A-CDKN2B locus on the 9p21 chromoso-
mal band encodes the proteins p14ARF, p16INK4A and
p15INK4B. p14ARF-mdm2-p53 and p16INK4A/
p15INK4B-Rb1 pathways are important for controlling the
cell cycle, especially progression between G1 and S phas-
es.90 Combined CDKN2A-CDKN2B deletion has been
linked to aggressive behavior in cutaneous T-cell lym-
phomas,91-95 but more rarely in pcALCL, as confirmed by
two research groups.95,96
Other cytogenetic abnormalities in primary cutaneous
anaplastic large cell lymphoma
Additional chromosomal alterations, such as gains of
7q31 and losses on 6q16-6q21, 6q27 and 13q34 regions,
are recurrently present in pcALCL.31,62,97 Interestingly, these
alterations in pcALCL occur mainly in telomeric and cen-
tromeric regions. Genomic imbalances have been found in
chromosomal regions coding for FGFR1 (8p11), NRAS
(1p13.2), MYCN (2p24.1), RAF1 (3p25) and others.98
Targeted therapies for primary cutaneous 
CD30-positive lymphoproliferative disorders
Currently, complete surgical excision and local radio-
therapy are the recommended first-line therapies for soli-
tary or grouped localized pcALCL lesions.99 However, the
most appropriate treatment in the relapsed/refractory set-
ting has not been clearly identified. Multiagent
chemotherapy is customarily indicated for extracutaneous
tumor spread beyond locoregional lymph nodes. In recent
years, brentuximab vedotin, an anti-CD30 antibody-drug
conjugate has been proposed as one of the best options for
achieving complete remission with low toxicity in these
patients.100 ALCANZA, an international, open-label, ran-
domized, phase 3, multicenter clinical trial, has shown sig-
nificant improvement in objective responses lasting at
least 4 months with brentuximab vedotin compared with
the physician’s choice of methotrexate or bexarotene in
CD30+ cutaneous T-cell lymphomas, especially MF and
pcALCL (having excluded Sézary syndrome and LyP from
the study, since these are entities in which brentuximab
vedotin is successful).101 The mean duration of response to
this drug in pcALCL is 7.6 months. Peripheral neuropathy
and fatigue are the most commonly reported adverse
events (in 57.2% and 35.6% of cases, respectively).102
Recently the US Food and Drug Administration and the
European Medicines Agency approved the use of brentux-
imab vedotin in cutaneous T-cell lymphomas. 
Besides the use of anti-CD30 molecules in the treatment
of primary cutaneous CD30+ lymphoproliferative disor-
ders, molecular data generated in the study of pcALCL
offer multiple opportunities for targeted therapies (Figure
4). 
The recognition of convergent mutations and kinase
fusions leading to STAT3 activation in a subgroup of
pcALCL could allow the use of JAK1/2/3 inhibitors in the
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treatment of this subgroup.68,103 In addition, patients with
the rare subtype of ALK+ pcALCL could benefit from ther-
apy with the ALK kinase inhibitor crizotinib, and other
new-generation inhibitors such as alectinib or ceritinib.104
KIR3DL2 (CD158K) is a killer cell immunoglobulin-like
receptor normally expressed by minor subsets of circulat-
ing CD8+ lymphocytes and natural killer cells.105 In con-
trast, tumor cells of pcALCL and CD30+ lymphoprolifera-
tive disorders, which are derived from cell lines Mac2a
and Mac2b, express KIR3DL2 strongly.105 In Sézary syn-
drome, the expression of KIR3DL2 in malignant blood
cells has been proposed as a marker of blood tumor bur-
den.106 The novel agent IPH4102 is a monoclonal antibody
directed against KIR3DL2 that has proven effective in in
vitro cell lines of advanced pcALCL.47
The NOTCH pathway is activated in pcALCL as a con-
sequence of various mutations.89 Deregulated activity of
the NOTCH pathway can be inhibited using gamma sec-
retase inhibitors, as has been shown in an in vitro experi-
ment.89
Finally, therapies acting at the epigenetic level, based on
the mutations and epigenetic alterations described above,
could be useful in pcALCL. More specifically, romidepsin
and vorinostat, inhibitors of histone deacetylase, derived
from the bacterium Chromobacterium violaceum are effec-
tive at inducing apoptosis with an antitumor effect in
cutaneous T-cell lymphomas, alone and in combina-
tion.107,108 Recently, researchers from the Yale School of
Medicine, using cell lines derived from patients with
advanced MF and Sézary syndrome (MyLa, Sez4, HH,
Hut78), observed in vitro that bromodomain and extrater-
minal (BET) protein inhibitors are synergistically potenti-
ated by BCL2 inhibitors (e.g., venetoclax) and histone
deacetylase inhibitors (e.g., vorinostat and romidepsin) in
cutaneous T-cell lymphomas with MYC oncogene ampli-
fication.109 Patients with cutaneous CD30+ lymphoprolif-
erative disorders with MYC-induced Id2 overexpression
could also be candidates for this therapy.24
Recently, it was proposed that miR-155 inhibition
could be used in combination with apoptotic treatments
L. Prieto-Torres et al.
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Figure 4. New targeted therapies in advanced primary cutaneous anaplastic large cell lymphoma.  Brentuximab vedotin is a drug composed of a chimeric anti-CD30
antibody linked to four monomethyl auristatin (MMAE) molecules (on average) (1). This antibody-drug conjugate first binds to CD30 on the surface of pcALCL cells
(2). It is then internalized by a receptor-mediated endocytosis process (3 and 4). The resultant vesicle fuses with lysosomes (4), leading to proteolytic cleavage of the
dipeptide linker and the presence of free MMAE molecules, which inhibit tubulin polymerization of the cellular cytoskeleton and arrest growth of pcALCL tumor cells.
Gamma-secretase (γ-secretase) inhibitors prevent release of intracellular NOTCH1 (ICN1) from membrane-tethered heterodimeric NOTCH1 protein. This causes the
downregulation of the tumor cell nuclear factor-kB (NFKB) pathway and the inactivation of survival genes. JAK1/2/3 inhibitors are effective in vitro for controlling
pcALCL cell growth. This mechanism involves oncogenic JAK1 or STAT3 mutations associated with the hyperactive pSTAT3 shown in pcALCL with an NPM1-TYK2 gene
fusion and oncogenic STAT3 activation. In addition, anti-ALK molecules such as crizotinib, alectinib, and ceritinib in pcALCL patients with ALK rearrangements could
downregulate the STAT3 pathway, ultimately inducing tumor-cell death. IPH4102 is a humanized monoclonal antibody directed against the cellular receptor KIR3DL2
(CD158K). This receptor has been shown to be aberrantly expressed in advanced pcALCL. IPH4140 targets KIR3DL2 in tumor cells and promotes cell lysis after link-
ing to the CD16 activating receptor through antibody-dependent, cell-derived cytotoxicity mediated by NK cells. At the epigenetic level, histone deacetylase (HDAC)
inhibitors and demethylating agents have demonstrated a degree of effectiveness at inducing cell-cycle arrest, differentiation and/or apoptosis of tumor cells.
and checkpoint inhibitors in MF patients.110 MiR-155 is
also upregulated in pcALCL,77 providing an additional
therapeutic opportunity for these tumors.
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